exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088321 RNA Name: hsa-miR-382-5p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101054316 End Site(bp): 101054337 External Links: hsa-miR-382-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand APCDD1 chr18 10454635 10489949 + BCAS2 chr1 114567557 114581629 - BCL2L11 chr2 111119378 111168445 + CAMTA1 chr1 6785454 7769706 + COBLL1 chr2 164653624 164843679 - ELK1 chrX 47635521 47650604 - FOSL1 chr11 65892049 65900573 - IGF2BP3 chr7 23310209 23470491 - KMT5A chr12 123383773 123409353 + MAPRE2 chr18 34976928 35143470 + NID1 chr1 235975830 236065109 - PARM1 chr4 74933095 75050115 + PDE8A chr15 84980440 85139145 + RAB18 chr10 27504174 27542237 + SCAF11 chr12 45919131 45992120 - SH3GL1 chr19 4360370 4400547 - STEAP3 chr2 119223831 119265652 + STK40 chr1 36339624 36385896 - TAGLN chr11 117199370 117207464 + TUB chr11 8019244 8106112 + UBN2 chr7 139230356 139308236 + WDR4 chr21 42843094 42879568 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC092718.4 chr16 81030770 81031485 + AC126365.1 chr17 20788071 20789584 + FGD5-AS1 chr3 14920347 14948424 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.